Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Jaffee

Showing results (211-220 of 291) with videos related to

Pageof 30
Sort By:
Science (New York, N.Y.)|March 7, 2009
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility geneSiân Jones, Ralph H Hruban, Mihoko Kamiyama, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2016
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic CancerAaron T Wild, Joseph M Herman, Avani S Dholakia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic CancerAnnie A Wu, Katherine M Bever, Won Jin Ho, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerDung T Le, Andrea Wang-Gillam, Vincent Picozzi, et al.
Cancer Discovery|June 15, 2019
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated FibroblastsEla Elyada, Mohan Bolisetty, Pasquale Laise, et al.
Science Advances|February 7, 2024
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cellsJunke Wang, Jessica Gai, Tengyi Zhang, et al.
Cancer Medicine|December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancerMark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.
Pageof 30

Showing results (211-220 of 291) with videos related to

Sort By:
Pageof 30
Science (New York, N.Y.)|March 7, 2009
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility geneSiân Jones, Ralph H Hruban, Mihoko Kamiyama, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2016
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic CancerAaron T Wild, Joseph M Herman, Avani S Dholakia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic CancerAnnie A Wu, Katherine M Bever, Won Jin Ho, et al.
Cancer Immunology Research|January 12, 2026
A randomized phase II study: CRS207/GVAX plus anti-PD1 and anti-CTLA4 recruits mesothelin- and mKRAS-specific T cells into PDACKatherine M Bever, Amanda L Huff, Ludmila Danilova, et al.
Cancer Immunology Research|August 14, 2014
A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancerGang Chen, Richa Gupta, Silvia Petrik, et al.
Annals of Surgery|July 14, 2020
Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic CancerToni T Seppälä, Jacquelyn W Zimmerman, Elisabetta Sereni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2015
Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancerDung T Le, Andrea Wang-Gillam, Vincent Picozzi, et al.
Cancer Discovery|June 15, 2019
Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated FibroblastsEla Elyada, Mohan Bolisetty, Pasquale Laise, et al.
Science Advances|February 7, 2024
Neoadjuvant radioimmunotherapy in pancreatic cancer enhances effector T cell infiltration and shortens their distances to tumor cellsJunke Wang, Jessica Gai, Tengyi Zhang, et al.
Cancer Medicine|December 27, 2019
A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancerMark Yarchoan, Chiung-Yu Huang, Qingfeng Zhu, et al.
Pageof 30